Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 5/20 | 0.60 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | DHFR | P00374 | 1/20 | 0.54 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30362841 | 0.81 | MAOB (0.61) | MAOBMAOAMAPTGAARAB9A | |
| SCHEMBL2648020 | 0.81 | MAOB (0.61) | MAOBMAOAMAPTGAARAB9A | |
| SCHEMBL6816900 | 0.80 | MAOB (0.59) | MAOBMAOAMAPTDHFRNPSR1 | |
| SCHEMBL457443 | 0.80 | P4HTM (0.53) | MAOBMAOAMAPTGAARAB9A | |
| SCHEMBL14067178 | 0.80 | LMNA (0.62) | MAOBMAOAMAPTGAARAB9A | |
| SCHEMBL18297527 | 0.80 | MAOB (0.55) | MAOBMAOAMAPTGAARAB9A | |
| SCHEMBL1713718 | 0.80 | P4HTM (0.53) | MAOBMAOAMAPTGAARAB9A | |
| Hydrochloric Acid SCHEMBL1330115 | 0.79 | MAOB (0.59) | MAOBMAOAMAPTGAARAB9A | |
| SCHEMBL28646599 | 0.78 | RAB9A (0.52) | MAOBMAOAMAPTGAARAB9A | |
| SCHEMBL875608 | 0.78 | LMNA (0.53) | MAOBMAOAMAPTGAARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023009708-A1 | HETEROARYLOXY TRIAZOLO- AND IMIDAZO-AZINES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| CN-105431149-B | Neuroprotective multifunctional antioxidants and their monofunctional analogs | 彼得·F·卡罗 | 2019-06-11 | — | — | CN | disclosed |
| EP-2956140-B1 | NEUROPROTECTIVE MULTIFUNCTIONAL ANTIOXIDANTS AND THEIR MONOFUNCTIONAL ANALOGS | KADOR PETER F (US) | 2018-07-11 | — | — | EP | disclosed |
| CN-105431149-A | Neuroprotective multifunctional antioxidants and their monofunctional analogs | KADOR PETER F | 2016-03-23 | — | — | CN | disclosed |
| EP-2760843-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2760843-B1 | SELECTIVE NR2B ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2956140-A1 | NEUROPROTECTIVE MULTIFUNCTIONAL ANTIOXIDANTS AND THEIR MONOFUNCTIONAL ANALOGS | Kador, Peter F. (US) | 2015-12-23 | — | — | EP | disclosed |
| EP-2149563-B9 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2149563-B1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-01-07 | — | — | EP | disclosed |
| US-8877766-B2 | Neuroprotective multifunctional antioxidants and their monofunctional analogs | BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA | 2014-11-04 | — | — | US | disclosed |
| US-20100249148-A1 | NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME | KOWA COMPANY, LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7790737-B2 | Substituted pyrimidine compounds and their utility as CETP inhibitors | KOWA COMPANY, LTD. (JP) | 2010-09-07 | — | — | US | disclosed |
| CN-101679309-A | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound | KOWA CO | 2010-03-24 | — | — | CN | disclosed |
| CN-101679363-A | Novel pyrimidine compound having benzyl(heterocyclicmethyl)amine structure and pharmaceutical product containing the same | KOWA CO | 2010-03-24 | — | — | CN | disclosed |
| US-7659271-B2 | Pyrimidine compound having dibenzylamine structure and medicament comprising the same | KOWA COMPANY, LTD. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-2149563-A1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | Kowa Company. Ltd. (JP) | 2010-02-03 | — | — | EP | disclosed |
| EP-2138489-A1 | NOVEL PYRIMIDINE COMPOUND HAVING BENZYL(HETEROCYCLICMETHYL)AMINE STRUCTURE AND PHARMACEUTICAL PRODUCT CONTAINING THE SAME | Kowa Company. Ltd. (JP) | 2009-12-30 | — | — | EP | disclosed |
| US-20090105269-A1 | Multifunctional Compounds and Methods of Use Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-23 | — | — | US | disclosed |
| US-20090082352-A1 | N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) | KOWA COMPANY, LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090062306-A1 | NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME | KOWA COMPANY, LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082352-A1 | N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) | CETP, NPC1L1, MTTP | MAOB 4298/4885MAOA 4567/4885MAPT 3761/4885 |
| US-20100249148-A1 | NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME | CETP, MTTP, NPC1L1 | MAOB 2649/4885MAOA 3454/4885MAPT 3936/4885 |
| US-20090062306-A1 | NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME | CETP, MTTP, NPC1L1 | MAOB 2649/4885MAOA 3454/4885MAPT 3936/4885 |
| US-20090105269-A1 | Multifunctional Compounds and Methods of Use Thereof | AS3MT, OAT, NCL | MAOB 221/4885MAOA 378/4885MAPT 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.